VC/PE  Bain Capital Life Sciences

https://www.baincapital.com/businesses/scalin g-innovation-life-sciences





     Office Locations:

200 Clarendon St.
Boston, MA 02116
Phone: 617-516-2000

 

Stages:

  • Early
  • Expansion
  • Growth
  • Middle Market


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. Bain Capital Life Sciences targets four types of investment opportunities: Engagement with companies at the critical development stages of innovation; Partnering with companies to accelerate and expand platforms; Engaging with companies at a crossroads to create value; and Collaborating with the Bain Capital platform to invest in and support larger companies



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Adam M. Koppel Managing Director
    Andrew Hack Managing Director
    Jeffrey Schwartz Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      07/20/2021


      Amylyx Pharmaceuticals


      MA


      $135,000,000


      Series C


      03/04/2021


      Amunix


      CA


      $117,000,000


      Series B


      02/25/2021


      Xilio Therapeutics


      MA


      $95,000,000


      Series C


     

    Portfolio companies include:

     

    Recent News: